Cingulate (CINGW) Amortization of Deferred Charges (2025)
Cingulate's (CINGW) quarterly Amortization of Deferred Charges came in at $4694.0 in Q4 2025, up 103.52% quarter-over-quarter from -$133304.0 in Q3 2025.
Powered by 
Analysis
Cingulate (CINGW) Amortization of Deferred Charges (2025) Analysis & Trends
Cingulate (CINGW) has reported Amortization of Deferred Charges for 1 consecutive years, with $4694.0 the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Amortization of Deferred Charges changed N/A year-over-year to $4694.0; the trailing twelve-month figure through Dec 2025 stood at $26525.0 (changed N/A YoY), and the FY2025 full-year result was $26525.0, changed N/A from the prior year.
- Amortization of Deferred Charges advanced to $4694.0 in Q4 2025 per CINGW's latest filing, from -$133304.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $78159.0 in Q2 2025 and bottomed at -$133304.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.03 Bn | 625.27 Bn | 17.26 Bn |
| 2 | AbbVie | 441.99 Bn | 435.42 Bn | 12.70 Bn |
| 3 | Merck | 366.30 Bn | 359.16 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.55 Bn | 258.86 Bn | 11.24 Bn |
| 5 | Pfizer | 159.14 Bn | 147.45 Bn | 10.94 Bn |
| 6 | Sanofi | 52.40 Bn | 45.02 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 44.13 Bn | 44.13 Bn | - |
| 8 | Incyte | 25.53 Bn | 20.99 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.51 Bn | 18.85 Bn | 683.80 Mn |
| 10 | Cingulate | 100,214.03 | 100,214.03 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 4,694.00 |
| Sep 30, 2025 | -133,304.00 |
| Jun 30, 2025 | 78,159.00 |
| Mar 31, 2025 | 76,976.00 |